Abnova’s EUA Approved COVID-19 Viral Extraction Kit Captured More Significant Orders as Market Demand Outpaced Supply

Neihu, Taiwan (July 01, 2020)

Abnova announced today that its COVID-19 viral extraction kit has captured more significant orders as market demand outpaced supply. The increase reflects the surge in demand following the EUA approval of Abnova’s COVID-19 viral extraction kit. More significantly, it also reflects the resurgence of new COVID-19 cases since reopening not only in the US but also in Japan, Korea, and China, and in India with short COVID-19 lockdown. Beginning July and coming months, Abnova will start shipping out the cumulative orders to the customers while ensuring uninterrupted raw material supply chain and maintaining high product quality.

To meet the challenge, Abnova has put in place COVID-19 specialized teams in procurement, production, quality assurance, and customer service. Supply chain capability has become more critical as companies compete for raw materials and manufacture the deliverables for the customers. Abnova also quickly shifted from managing a diverse portfolio of products with small quantity (100ug) to few products with large quantity (100K assays). Quality assurance are even more critical in large quantity shipment. Given the COVID-19 reopening instability, Abnova have also setup customer services for each countries.

In every clinical laboratories in each countries, viral RNA extraction has become an indispensable procedure prior to COVID-19 RT-PCR assay. Upstream RNA quality have a big impact on downstream RT-PCR quality for COVID-19 viral identification. EUA guidelines and certification have become stricter and gaining approval becomes more difficult. EUA certification process aims to uphold of the product performance and quality. Non-certified products will be less competitive in the increasingly competitive market. Nonetheless, the unabated COVID-19 outbreak continues to drive up market demand.